Advanced functional MRI scans from the Alzheimer’s clinical trial revealed preserved synaptic density in the hippocampus region among treated patients, providing neuroimaging validation for the drug’s therapeutic mechanism.
Neuroscientists stated that biomarker tracking through non-invasive imaging will allow clinicians to monitor patient responses and tailor therapeutic interventions with high precision.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.news2026.example.com/alzheimers-research-8